Solar Foods, a growth company listed on the stock exchange, has been awaiting sales approval for its innovative Solein protein in Europe and Britain for 4.5 years, according to the company's CEO Rami Jokela during an interview with Kauppalehti's Talousaamu. Jokela expressed uncertainty about when the approval might finally be granted and suggested that more discussions would need to take place in Brussels to expedite the process. While they hope to receive the approval this year, there’s speculation that the UK might issue a decision sooner than the EU.

In contrast, Solar Foods is making progress in the United States, where the Solein protein is expected to reach consumers in the first half of the year, highlighting a significant shift in their market strategy. Jokela mentioned that while he couldn't disclose the exact timing for when customers could expect the product, he anticipated it would be just a few weeks to months away from being available on the market. This timeline suggests a positive outlook for the company amid the lengthy regulatory process in Europe.

The U.S. market represents a pivotal opportunity for Solar Foods, as it is the largest protein market globally. The company's efforts here may mark a critical milestone in establishing its presence in a highly competitive industry, with the potential to drive growth and innovation in the food sector. The delay in Europe, however, raises questions about the regulatory environment for food innovations and the challenges companies face in bringing new products to market in a timely manner.